Outlook Therapeutics Inc. announced that LYTENAVA™ received FDA approval as the first and only FDA-approved ophthalmic bevacizumab for the treatment of wet AMD.
The company said LYTENAVA is anticipated to have 12 years of market exclusivity under the Biologics Price Competition and Innovation Act (BPCIA).
Outlook Therapeutics said LYTENAVA is expected to be available to U.S. patients before year-end.
OTLK•
